Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials

Clinical Trials

Triphase begins Phase I trial of marizomib-bevacizumab combination to treat glioblastoma By PBR Staff Writer
Canada-based Triphase Accelerator has started a Phase I proof-of-concept clinical trial of marizomib, a highly potent proteasome inhibitor, for the treatment of patients with glioblastoma, the most common and aggressive malignant primary brain tumor.
Contract Research & Services > Clinical Trials > News
ChemoCentryx begins Phase Ib trial of CCX872 to treat pancreatic cancer By PBR Staff Writer
US-based biopharmaceutical firm ChemoCentryx has started patient enrollment in a Phase Ib clinical trial with its clinical compound, CCX872, to treat non-resectable pancreatic cancer.
Contract Research & Services > Clinical Trials > News RegeneRx JV retains Ora to conduct RGN-259/GBT201 clinical trials in US By PBR Staff Writer
RegeneRx Biopharmaceuticals' US joint venture with G-treeBNT (ReGenTree) has retained Ora to conduct a Phase III trial for the orphan disorder, neurotrophic keratopathy (NK) as well as a Phase IIb/III dose-response, confirmatory trial for dry eye syndrome (DES) in the US.
Contract Research & Services > Clinical Trials > News
See more Clinical Trials news

Latest Clinical Trials News and Insight

View all Clinical Trials news or find news targeted to your interests
ChemoCentryx begins Phase Ib trial of CCX872 to treat pancreatic cancer
By PBR Staff Writer
US-based biopharmaceutical firm ChemoCentryx has started patient enrollment in a Phase Ib clinical trial with its clinical compound, CCX872, to treat non-resectable pancreatic cancer.
Contract Research & Services > Clinical Trials > News
RegeneRx JV retains Ora to conduct RGN-259/GBT201 clinical trials in US
By PBR Staff Writer
RegeneRx Biopharmaceuticals' US joint venture with G-treeBNT (ReGenTree) has retained Ora to conduct a Phase III trial for the orphan disorder, neurotrophic keratopathy (NK) as well as a Phase IIb/III dose-response, confirmatory trial for dry eye syndrome (DES) in the US.
Contract Research & Services > Clinical Trials > News
MedDay reports positive MD1003 Phase III trial results in patients with progressive MS
By PBR Staff Writer
French biotechnology firm MedDay has reported positive results from its pivotal Phase III clinical trial (MS-SPI) of its investigational medicine, MD1003, to treat progressive multiple sclerosis (MS).
Contract Research & Services > Clinical Trials > News
Isarna starts first-in-human ISTH0036 Phase I trial to treat glaucoma
By PBR Staff Writer
Isarna Therapeutics has initiated a Phase I clinical trial with ISTH0036, an antisense oligonucleotide selectively targeting TGF-β2, to treat advanced glaucoma.
Contract Research & Services > Clinical Trials > News
PRA Health Sciences, Inc. Reports 4th Quarter and Full Year 2014 Results and 2015 Guidance
PRA Health Sciences, Inc. reported its financial results for the fourth quarter ended December 31, 2014.
Contract Research & Services > Clinical Trials > Press Releases
PRA Health Sciences Expands Global Phase I Patient Strategy
PRA Health Sciences (PRA) is enhancing its global Phase I patient strategy and increasing its clinical footprint with the expansion of its Early Development Services (EDS). These initiatives are being undertaken in response to market demand to include patients as early as possible in early phase clinical trial development and include:
Contract Research & Services > Clinical Trials > Press Releases
Arrowhead gets FDA clearance to begin Phase IIb trial of ARC-520 to treat chronic HBV
By PBR Staff Writer
The US Food and Drug Administration (FDA) has granted clearance for Arrowhead Research's (ARWR) investigational new drug (IND) application to proceed with a multiple-dose Phase IIb clinical trial of ARC-520, its clinical candidate to treat chronic hepatitis B virus (HBV) infection.
Contract Research & Services > Clinical Trials > News
Pharmacyclics reports positive longer-term results from Imbruvica Phase II trial in WM patients
By PBR Staff Writer
US-based biopharmaceutical firm Pharmacyclics has reported positive results from its Phase II investigator-initiated trial of Imbruvica (ibrutinib) in patients with Waldenstrom's macroglobulinemia (WM).
Contract Research & Services > Clinical Trials > News
Advaxis, RTOG Foundation partner on Phase II/III trial of ADXS-HPV in anal cancer
By PBR Staff Writer
US-based biotechnology firm Advaxis is entering into a clinical trial collaboration agreement with the Radiation Therapy Oncology Group (RTOG) Foundation to evaluate the safety and efficacy of ADXS-HPV (ADXS11-001) in a pivotal Phase II/III anal cancer trial.
Contract Research & Services > Clinical Trials > News
Neurotrope selects WCT to begin services for Phase IIB trial of bryostatin to treat AD
By PBR Staff Writer
Neurotrope Bioscience has selected Worldwide Clinical Trials (WCT), a clinical research organization (CRO) to start pre-patient enrollment activities to conduct a Phase IIb trial of its compound bryostatin-1 to treat Alzheimer's disease (AD).
Contract Research & Services > Clinical Trials > News
View all Clinical Trials news or find news targeted to your interests